Innoscripta (1INN) Q1 2025 earnings summary

Executive summary

• A limited review of the consolidated interim financial statements for Q1 2025 was conducted, confirming compliance with German commercial law and proper accounting standards.

• No material findings or indications of misstatements were identified; the financial statements present a true and fair view of the group's assets, financial, and earnings position.

• The review was based on plausibility checks, interviews, and analytical procedures, not a full audit.

Financial highlights

• Revenue for Q1 2025 was €25.58 million, up from €11.48 million in Q1 2024.

• Net income after taxes for Q1 2025 was €3.34 million, compared to €10.93 million in Q1 2024.

• Cash flow from operating activities reached €14.21 million, up from €2.94 million year-over-year.

• Total assets as of March 31, 2025, were €74.83 million, up from €39.86 million a year earlier.

• Equity increased to €35.15 million as of March 31, 2025, from €21.41 million at the end of Q1 2024.

Outlook and guidance

• No significant events after the reporting period were reported by management, and the going concern assumption remains valid.